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Arabia Methods: Retrospective cohort study for patients admitted to surgi-
cal wards at a tertiary care center in Jeddah, Saudi Arabia over 3 months. Three 
broad spectrum antibiotics were targeted; piperacillin/tazobactam, imipenem, 
and meropenem. De-escalation delay was measured in days from the time of 
getting the culture identification and susceptibility until narrowing the antimi-
crobial therapy to target the identified organism. The cost impact was measured 
by multiplying the period that patients were on broad spectrum antibiotics after 
the final identification and susceptibility of microorganism by the cost of broad-
spectrum antibiotics per day. Results: One hundred sixty-three patients received 
broad spectrum antibiotics over 3 months on surgical wards at our institution. 
Sixty four out 163 patient (39.2%) had identified organism and susceptibility for 
other antibiotics. Thirty one patients (48.4%) had de-escalation of antimicrobial 
therapy within 24 hrs of culture identification and susceptibility result. Thirty 
three patients (51.6%) had a delay in their broad spectrum antibiotics therapy 
de-esclation despite getting the culture identification and susceptibility. The total 
delay of broad spectrum antibiotics and cost impact were as follow: piperacillin/
tazobactam 267 days (3,920 USD); imipenem 5 days (230 USD); meropenem 110 
days (9,925 USD). ConClusions: the delay of broad spectrum antibiotics de-
escalation on surgical wards at our hospital has resulted in a cost impact of 14,075 
USD over 3 months period. Pharmacy intervention program on surgical wards to 
enforce the de-escalation process is needed.
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objeCtives: Health-care acquired infections (HCAIs) and resulting antibiotic treat-
ments have been raising global concerns. HCAIs represent a substantial economic 
and humanistic burden with increasing costs, morbidity and mortality. Concerns 
around antibiotic use include resistance and lack of new products to market. The 
latter is related to difficulty in gaining approval, potential lack of profitability, 
complicated market assess, and difficulty in demonstrating value. Methods used 
for economic evaluations may contribute to the difficulty in assessing antibiot-
ics. Our objective was to review published economic evaluations of antibiotics in 
HCAIs and to summarize currently used methods and challenges in assessing 
cost-effectiveness. Methods: We conducted a MEDLINE search for model-based, 
health economic evaluations of antibiotics in the six most prevalent HCAIs in the 
UK (respiratory tract, urinary tract, surgical site, clinical sepsis, gastrointestinal and 
bloodstream infections). Original, English language studies were included. Among 
others, analysis type, model structure, perspective, time horizon and outcomes were 
extracted. Results: We identified 126 papers, of which 19 met the inclusion criteria. 
These included 13 cost-effectiveness, four cost-consequence, one cost-minimization 
and one cost-benefit analyses. Of the models 12 were decision trees/decision mod-
els, three cost-calculators, one Markov model and one discrete even simulation. 2 
papers did not report sufficient methodology. Time horizons were mainly the length 
of an infection. Main outcomes were cost-per cure, cost-per patient treated, cost-
per QALY and total cost saving. Economic models tend not to account for changes 
in prevalence of resistance, and additional potential benefits such as preventing 
transmission of resistance. ConClusions: Most identified economic evaluations 
were simplistic, using cost-effectiveness approach through a simple decision tree, 
over short time-horizon, with payer perspective. This limits the flexibility of the 
evaluations to account for benefits of antibiotics in addressing burden of HCAIs and 
the current global concerns, contributing to the difficulty of assessing economic 
benefit of antibiotics.
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objeCtives: During the years, acute bacterial skin and skin structure infections 
(ABSSSIs) have seen an increase in incidence in many parts of the western world. 
Additionally, the treatment of ABSSSIs, generally consisting of surgical debride-
ment or drainage and empiric antibiotics in the hospital, can be further compli-
cated by emerging multi drug resistant bacteria, most notably methicillin-resistant 
Staphylococcus aureus (MRSA). As the incidence rates increase alongside with ris-
ing antibiotic resistance, ABSSSIs are becoming a significant burden for healthcare 
systems. This study aims to collect evidence on the healthcare resource utilization 
of ABSSSI and the economic implications of different treatment modalities for 
the management of these diseases. Methods: A systematic literature search in 
MEDLINE, Cochane and ISPOR abstract databases with predefined inclusion criteria 
and subsequent quality assessment was performed. Results: The search identi-
fied 1,799 unique publications of which 26 contained relevant economic data on 
ABSSSIs treatment and were therefore included in this manuscript. There were six 
healthcare resource utilization studies, 11 cost analyses, three cost-minimization 
and six cost-effectiveness analyses, of which only a single study reported quality 
adjusted life years. Vancomycin was evaluated in most studies (21), followed by lin-
ezolid (15), daptomycin (8) and others (7). ConClusions: This review provides an 
in-depth overview of the economic implications of current ABSSSI management. 
Major cost drivers of ABSSSI treatment were length of hospital stay and the overall 
cost associated with frequent intravenous antibiotics administration. While most 
studies (20) applied a hospital perspective, there was a substantial disparity on the 
specific costs in- or excluded in the analysis, and on the unit prices. This led to 
significant variations of the final cost outcomes. Notably, over 10-fold differences 
were found. The overall quality and comparability of the literature reviewed was 
sub-optimal, elevating the need for more high-quality and reproducible economic 
evaluations in the area of ABSSSIs.
a 5 year-horizon budget impact analysis of SOF-based regimens for the manage-
ment of HIV/HCV-coinfected patients Methods: This prospective study involved 
4 Italian Infectious Diseases Departments in the Liguria Region. A total of 1.005 
coinfected patients (30% cirrhotics) in any stage of their hepatic disease stages 
was considered (F0-F4, cirrhosis,transplanted,HCC). Disease stage costs per patient 
were collected, taking into account the rate of expected disease progression in 
absence of treatment and the rate of Sustained Virological Response (SVR)with 
SOF-based regimens. The success rate for SOF-based Regimens was estimated 
based on literature data, whilst the liver disease progression in a such short period 
was evaluted according to expert opinion. Drugs prices used in the calculation 
were those paid by the Italian Health Service. Two scenarios were compared: ”no 
treatment” versus b) SOF-based treatment. Data were analyzed from the Regional 
Health Service standpoint Results: Over the next 5 years, the total expense in 
a “no treatment” scenario (base case) should approximate 54 M Euros. Assuming 
an SVR success rate of 90%, average SOF-based regimens price higher than € 
50.000 costs more than € 55 millions, resulting not convenient. At the average 
price of 15.000 € per patient, the total expense in the SOF-based scenario should 
approach 20 MEuros , i.e. more than 60% lower than in the “no-treatment” sce-
nario. ConClusions: The results suggest that at the average price of € 15.000 
per patient over the next 5 years, the use of SOF should allow saving half of the 
economic resources needed to manage the HIV/HCV disease population.
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objeCtives: The purpose of this study is to estimate the 5-year budget impact 
of a pneumococcal vaccination program of population aged 65-year-old in 
Spain. Methods: A dynamic model based on differential equations was built for 
the conceptualization of the disease and the parameters were populated with the 
vaccine efficacy data coming from the CAPITA clinical trial of the 13-valent pneu-
mococcal conjugate vaccine (PCV13). If S stands for susceptible, I for infective, V 
shows the number of individuals who are effectively vaccinated at each time and 
t is the time variable and the parameters beta and gamma show the transmission 
and natural recovery coefficients respectively, the differential equation of the model 
is: dS(t)/dt= -β *I(t)*S(t)+γ *I(t)-V(t) and dI(t)/dt= +β *I(t)*S(t)-γ *I(t). Program duration was 
fixed to 5 years, and every year the 65-year cohort would be vaccinated (coverage 
of 49.3%). Economic parameters included hospital costs of treating pneumonias, 
meningitis, bacteremia, and empyema as well as the outpatient costs of treating 
pneumonia in the community (41.5% of the cases). Costs sources were official data-
bases for hospitalizations and vaccine, and a local study for outpatient costs of 
pneumonia. Mortality rates related to pneumococcal infections reported in the UK 
are applied to the Spanish case. Results: In 5 years-period with a 65 year old cohort 
of 513,000 people, the vaccination program is expected to avoid about 35,700 cases 
of pneumococcal disease (the majority of them otherwise causing pneumonia), 
and about 1,419 related deaths. Vaccination costs of 59.5 million euros would be 
completely offset by medical cost reduction of 124 million euros, yielding to a net 
saving of 64.5 million euros. ConClusions: PCV13 vaccination targeting the cohort 
of 65 year-old Spanish adults is expected to result in net savings for the health care 
system in addition to significant cases of pneumonia avoided and related health 
improvements for the patients.
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objeCtives: New HCV antiviral treatments showed higher effectiveness (sustained 
virologic response - SVR) compared with that of available drugs. Due to the high cost 
of such treatments and in absence of scientific evidence on their economic impact 
on the Italian National Health Service (NHS), it is crucial to investigate the sustain-
ability of their use in the Italian setting. The study aimed at evaluating the budget 
impact on the Italian NHS of the use of Daclatasvir for HCV treatment. Methods: 
An analytical decision model was implemented with a five year time horizon. Two 
scenarios were structured considering the market shares of HCV treatments (expert 
opinion) with or without the use of Daclatasvir. The target population (HCV genotype 
3 infected patients) was estimated based on literature data. Patients enter the model 
in fibrosis stage 3 and 4 and may evolve in an SVR state (based on effectiveness 
data), decompensated cirrhosis, HCC, liver transplant or death. The costs considered 
in the analysis were those of antiviral treatment, adverse events management and 
health state costs. Results: The use of Daclatasvir, in comparison with the scenario 
without Daclatasvir, would lead to an increase of costs for the Italian NHS of 21.31 
million euros in year 1, 21.33 million euros in year 2, 23.36 million euros in year 
3, 23.26 million euros in year 4 and 17.20 million euros in year 5. ConClusions: 
Daclatasvir would lead to an increase of healthcare costs for the treatment of geno-
type 3 HCV infected patients in the first three years, followed by a reduction of the 
cost’s increase in years 4 and 5 (-0.44% in year 4 compared with year 3, and -26.0% in 
year 5 compared with year 4), thanks to the management of better health conditions, 
due to the higher effectiveness of Daclatasvir based therapies than the comparators.
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objeCtives: To measure the cost impact of the delay of broad spectrum antibi-
otics de-escalation on surgical wards at a tertiary care center in Jeddah, Saudi 
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objeCtives: To find out the average direct hospitalization cost and length of hos-
pital stay for patients infected with Carbapenem-resistant Klebsiella pneumonia 
(CRKp) and compare it with that of patients infected with Carbapenem-sensitive 
Klebsiella pneumonia (CSKp). Methods: A cross sectional study was carried out 
from January-December 2014 and the data for hospitalization cost was collected for 
the patients with CRKp and CSKp infections from the medicine ICU for 72 patients 
admitted to the hospital. The data was analyzed for the site of infection, length of 
stay and average direct hospitalization cost which was then compared between the 
two groups. Results: During the study period, 101 patients were diagnosed with 
Klebsiella pneumoniae infection. 61.79% of the infections were respiratory, 24.52% 
urinary tract- related, 13.2% systemic and 0.47% skin and soft tissue-related. The 
mean age of the study population was 51.7 ± 15.7 years. The median length of stay 
for CRKp was 12 (11; 23) days as compared to 8 (5.2; 13.2) days in CSKp patients . The 
median direct hospitalization cost was calculated to be INR 43,274 (24,898; 16,0315) 
in case of CRKp versus INR 23,452 (12,489; 47,349) in CSKp patients. ConClusions: 
We observed that the average cost of overall therapy and the average no. of hos-
pitalization days was higher in CRKp group compared to CSKp group. Antibiotic 
resistance is a growing phenomenon and the resistance to Carbapenems can lead 
to increased burden of morbidity and treatment cost for patients.
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objeCtives: Antibiotic resistance is known to be associated with increased burden 
of morbidity, mortality and treatment costs all over the world. Methicillin resistant 
Staphylococcus aureus is one of the most important gram positive bacteria which 
causes serious community acquired as well as hospital acquired infections. The 
objective of this study is to compare the direct costs and length of stay in MRSA ver-
sus MSSA infections among in-patients of the hospital. Methods: A cross sectional 
study was carried out from Jan-Dec 2013 and the hospitalization cost was collected 
for the patients with MRSA and MSSA infections from the medicine ICU and the 
microbiology department for 63 patients. The data was analyzed for the type of 
infection and the average hospitalization cost. The median hospitalization cost was 
calculated for both the group of patients. Results: Out of the 63 patients observed, 
44 (69.84%) patients were infected with MRSA and 19 (30.15%) were infected with 
MSSA. The median length of stay was 10 days in MRSA group as compared to 
7.5 days in MSSA group. The median hospitalization cost for MRSA infection was 
INR 16,383 and for MSSA it was INR 11,481. ConClusions: Methicillin resistance in 
Staphylococcus aureus is associated with increased length of stay and hospitaliza-
tion costs. Increased length of stay leads to further increase in the treatment costs 
and morbidity of the patients as it may lead to nosocomial infections.
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objeCtives: To compare the cost of the primary prophylaxis of invasive fungal infec-
tions (IFI) with voriconazole, posaconazole, and micafungin in patients undergoing 
allogeneic hematopoietic stem cell transplantation (HSCT) in hospitals of the National 
Health System (NHS) in Spain. Methods: A cost analysis was made for 100 days and 
180 days of prophylaxis and a decision tree model was developed. The efficacy rate 
of IFI prophylaxis, mortality rate from all causes in patients with/without IFI and 
survival rate with liposomal amphotericin B treatment of prophylaxis failures were 
obtained from randomized trials and a mixed treatment comparisons meta-analysis. 
The model simulation was interrupted with IFI treatment (prophylaxis failures). The 
costs of medication and its intravenous administration in the hospital (in the case of 
micafungin) were considered. Results: In the non-modeled analysis, the savings 
per patient of prophylaxis with voriconazole ranged from € 1,709 to € 9,655 compared 
with posaconazole oral solution, from € 1,811 to € 9,767 compared with posacona-
zole gastro-resistant tablets and from € 3,376 to € 7,713 compared with micafungin. 
In the modeled analysis, the mean cost per patient of the prophylaxis and treatment 
of IFIs was € 6,987 to € 7,619 with voriconazole, € 7,749 with posaconazole, and € 
22,424 with micafungin. Therefore, the savings per patient of prophylaxis with vori-
conazole was € 130 to € 3,664 and € 11,132 to € 30,374 compared with posaconazole 
and micafungin, respectively. The result remained stable after modification of the 
number of days of antifungal prophylaxis and the cost of antifungal treatment of 
failures. ConClusions: According to the model, antifungal prophylaxis with vori-
conazole in recipients of hematopoietic progenitor transplants, compared with posa-
conazole or micafungin, may represent savings for NHS hospitals in Spain.
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objeCtives: Darunavir and atazanavir are currently the only protease inhibitors 
(PIs) recommended by the British HIV Association (BHIVA) treatment guidelines. The 
Office of AIDS Research Advisory Council (OARAC) reviewed the US HIV guidelines 
in April 2015 and delisted atazanavir/ritonavir (ATV/r) from the preferred PI options 
as a result of better tolerability (primarily due to discontinuations caused by adverse 
events (AEs)) of darunavir/ritonavir (DRV/r) compared to ATV/r based on findings from 
the ARDENT trial. The objective of this analysis was to quantify the economic impact 
of treating patients with DRV/r compared to ATV/r for two years in the UK based on 
drug costs, AEs and discontinuation due to AEs. Methods: A simple Markov model 
was built in MS Excel with two health states and 6-month cycles (4 cycles in total): 
on treatment with DRV/r or ATV/r and on subsequent treatment. All patients start on 
DRV/r or ATV/r and some discontinue and move to a subsequent therapy (weighted 
average of 3rd agents in treatment experienced patients, £11.10/day at list price). 
Discontinuation rates from ARDENT were converted to 6-month rates (4.60% for DRV/r 
and 8.78% for ATV/r) using the method from Miller et al. Patients were assumed to 
attend 6 further consultant appointments (£325/visit) in the first three months after 
switching as advised in the BHIVA guidelines for monitoring. AEs from ARDENT were 
also included. Results: Using a list price of £10.57/day for DRV/r and £10.76/day for 
ATV/r), treatment with DRV/r saved £116 per patient in 6 months, £219 in one year 
and £393 over two years. Drivers of savings were the cost of consultant appointments 
and of subsequent treatment. Sensitivity analyses showed how DRV/r was cost saving 
even when the drug cost of DRV/r and ATV/r was assumed equal. ConClusions: In 
conclusion DRV/r has proven to be a highly tolerable and cost saving PI.
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objeCtives: Treatment of chronic hepatitis C is changing fast given the amount 
of new drugs coming to the market. Little is known about the budget impact and 
long term implications of the different treatment options. The objective of this 
study was to estimate the budget impact of different treatment options on national 
or regional level and to evaluate the short-term as well as long-term implications 
of different hepatitis C treatments. Methods: A model flexible for regional and 
national Swedish cohorts of hepatitis C patients was developed. Cost and effect 
inputs were taken from published sources and clinical trial data. Using the model, 
total budget impact as well as cost per cured patient was estimated for different 
treatments. In addition, long term consequences of different treatments were esti-
mated using a Markov model with transition probabilities from the published model 
in the field by Lidgren et al.(1) Results: Given efficacy rates of over 95%, the new 
treatments of hepatitis C will cure more patients in Swedish cohorts compared to 
previous treatments with efficacy rates of around 65%. In the long term, the supe-
rior effectiveness of the new treatments would translate into decreases in cases of 
decompensated cirrhosis, hepatocellular cancer and liver transplants of over 90% 
among these patients. ConClusions: The new treatments of hepatitis C could 
improve virologic outcomes among patients. In the long term, cost-savings from 
reduced burden of disease among these patients are also to be expected. However, 
in the short term these treatments will require twice the budget size compared to 
earlier antiviral therapies in this field. (1.) Lidgren M, Hollander A, Weiland O, Jonsson 
B. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, 
cost-effectiveness and quality of life. Scand J Gastroenterol. 2007 Jul;42(7):876-77
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objeCtives: To obtain long-term outcomes of using rilpivirine/tenofovir/emtricit-
abine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA< 100 000 
copies/ml in the Russian Federation. Methods: Cost analysis was based on the 
results of modeling the treatment of naïve HIV-infected patients with rilpivirine/
tenofovir/emtricitabine (single tablet regimen). Present analysis included assessment 
of direct (ambulatory treatment and hospitalization) and indirect costs (GDP losses). 
Cost data was based on median prices for medicines and medical services in National 
healthcare system in the Russian Federation. Results: The use of rilpivirine/tenofo-
vir/emtricitabine (single tablet regimen) in the analyzed population, due to the better 
adherance and, as a result, better viral suppression, leads to the lower number of new 
HIV-infected persons. Therefore in life-time perspective the potential total costs sav-
ings for the whole population can be up to 8% (€ 1 116 010 172) and 6% (€ 841 581 441) 
compared to efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + 
tenofovir/ emtricitabin (multi-pill regimen), respectively. ConClusions: Obtained 
results showed that better adherence on the treatment scheme rilpivirine/tenofovir/
emtricitabine (single tablet regimen) among naïve patients with HIV-1 RNA< 100 000 
copies/ml can lead to potential significant long-term cost savings.
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